Treatment with immune checkpoint inhibitors (ICIs) has improved the survival of patients with metastatic melanoma. However, although ICIs are promising for achieving lasting clinical responses, only a subset of patients receive substantial benefit. Our results suggest that the IL-17 pathway supports the response of melanoma to dual ICI therapy and might represent a biomarker for patient stratification.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Huang, A. C. & Zappasodi, R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23, 660–670 (2022). This review article summarizes the current state of the art of immunotherapeutic approaches in melanoma and provides mechanistic overview of immunotherapy response and resistance.
Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022). This paper reports the 6.5-year efficacy and safety outcomes of the CheckMate 067 trial.
Livingstone, E. et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet 400, 1117–1129 (2022). This paper reports the final efficacy and safety outcomes of the IMMUNED trial.
Iwakura, Y. et al. Functional specialization of interleukin-17 family members. Immunity 34, 149–162 (2011). This review article discusses the function and therapeutic potential of each member of the IL-17 family.
Chen, C. & Gao, F. H. Th17 cells paradoxical roles in melanoma and potential application in immunotherapy. Front. Immunol. 10, 187 (2019). This review article discusses TH17 cell functions in melanoma.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Váraljai, R. et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat. Cancer https://doi.org/10.1038/s43018-023-00610-2 (2023).
Rights and permissions
About this article
Cite this article
Immunotherapy responses of patients with metastatic melanoma are linked to IL-17 signaling. Nat Cancer 4, 1224–1225 (2023). https://doi.org/10.1038/s43018-023-00611-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00611-1
